November 11, 2026

To Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	To The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir / Madam,

Sub: Classification of US FDA Inspection at Lannett Company LLC, a wholly owned subsidiary of Aurobindo Pharma USA, Inc.

Ref: Our letter dated August 24, 2026

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that:

The United States Food and Drug Administration (US FDA) had conducted inspection at Lannett Company LLC, a wholly owned step-down subsidiary of the Company, located at Seymour, IN, USA from 17th to 21st August 2026. After the completion of inspection, the US FDA had issued four observations which we have responded to within the stipulated time.

The US FDA has now determined that the inspection classification of this facility is "official action indicated" (OAI).

The Company is committed to maintaining robust quality and compliance standards across its manufacturing facilities.

The Company will keep the Stock Exchanges informed of any further developments in this regard, as required under the applicable regulations.

Please take the above information on record.

Yours faithfully,
For AUROBINDO PHARMA LIMITED
Digitally signed by ADI REDDY BADDIGAM
Date: 2026.11.11 20:17:53 +05'30'

B. Adi Reddy
Company Secretary

Annexure

Sr. No.	Particulars	Details
1	Name of the authority	US Food and Drug Administration (US FDA), USA
2	Nature and details of the action(s) taken, initiated or order(s) passed by the Authority	The United States Food and Drug Administration (US FDA) had conducted inspection at Lannett Company LLC, a wholly owned step-down subsidiary of the Company, located at Seymour, IN, USA from 17th to 21st August 2026. After the completion of inspection, the US FDA had issued four observations.
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	November 11, 2026.
4	Details of the violation(s)/ contravention(s) committed or alleged to be committed	The US FDA has now determined that the inspection classification of this facility is "official action indicated" (OAI).
5	Impact on financial, operation, or other activities of the listed entity, quantifiable in monetary terms to the extent possible	There is no impact on the Company's financials or operations due to the said action.

Digitally signed by ADI REDDY BADDIGAM
Date: 2026.11.11 20:18:26 +05'30'